Evidence map›Paper›PMID 28676716›Full record

ArticleThe Journal of antibiotics2017

Synthesis and antibacterial activity of novel lincomycin derivatives. III. Optimization of a phenyl thiadiazole moiety.

Ko Kumura, Yoshinari Wakiyama, Kazutaka Ueda, Eijiro Umemura, Takashi Watanabe, Mikio Yamamoto, Takuji Yoshida, Keiichi Ajito

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ko KumuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Yoshinari WakiyamaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Kazutaka UedaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Eijiro UmemuraPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Takashi WatanabePharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Mikio YamamotoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Takuji YoshidaPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.
Keiichi AjitoPharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lincomycin derivatives that have a 5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl thio moiety at the 7-position were synthesized. 5-Substituted 2-nitrophenyl derivatives showed potent antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with erm gene. Antibacterial activities of the 4,5-di-substituted 2-nitrophenyl derivatives were generally comparable to those of telithromycin (TEL) against S. pneumoniae with erm gene and clearly superior to those of TEL against S. pyogenes with erm gene. Compounds 6 and 10c that have a methoxy group at the 5-position of the benzene ring exhibited activities comparable to TEL against Haemophilus influenzae. These results suggest that lincomycin derivatives modified at the 7-position would be promising compounds as a clinical candidate. We would like to dedicate this article to the special issue for late Professor Dr. Hamao Umezawa in The Journal of Antibiotics.The Journal of Antibiotics advance online publication, 5 July 2017; doi:10.1038/ja.2017.59.

Identifiers

PMID28676716
OpenAlexW2730768698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.